Lamensdorf Michael MD is categorized under Ophthalmologists in Sarasota, FL and active since 1984.
Lamensdorf Michael MD was established in 1984, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Ophthalmologists business, which does work in the B2C market, and is classified as a Ophthalmologists, under code number 6211110 by the NAICS.
If you are seeking more information, feel free to contact Michael Lamensdorf at the company’s single location by writing to 1428 South Tamiami Trail, Sarasota, Florida FL 34239 or by phoning (941) 957-4987. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Lamensdorf Michael MD |
| Contact Person: | Michael Lamensdorf |
| Address: | 1428 South Tamiami Trail, Sarasota, Florida 34239 |
| Phone Number: | (941) 957-4987 |
| Website Address: | eyespecialists-fl.com |
| Annual Revenue (USD): | $500.000 to $999.999 |
| Founded: | 1984 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Ophthalmologists |
| SIC Code: | 8011 |
| NAICS Code: | 6211110 |
| Share This Business: |
Lamensdorf Michael MD was started in 1984 to provide professional Ophthalmologists under the SIC code 8011 and NAICS code 6211110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.
Feel free to contact Michael Lamensdorf for inquiries that concern Lamensdorf Michael MD by calling the company number (941) 957-4987, as your correspondence is most welcome. Additionally, the physical location of the single location of Lamensdorf Michael MD can be found at the coordinates 27.32045,-82.52976 as well as the street address 1428 South Tamiami Trail in Sarasota, Florida 34239.
For its online presence, you may visit Lamensdorf Michael MD’s website at eyespecialists-fl.com and engage with its social media outlets through on Twitter and on Facebook.